(CTN News) – Eli Lilly and Co has recently unveiled a new website called Zepbound LillyDirect, which enables individuals to directly purchase medications from the company, including their weight-loss drug Zepbound.
In addition, the website aims to connect people with obesity and other medical conditions to telehealth companies. This move is a response to the growing demand for potent weight-loss drugs like Novo Nordisk’s Wegovy, which has been observed in the past year.
The obesity drug market is expected to reach around $100 billion by the end of the decade, attracting interest from weight management service providers such as WW International and Ro, who have also launched telehealth services for these drugs.
Following the launch of Lilly’s website, shares of WW International, formerly known as WeightWatchers, saw a decline of over 10% on Thursday. Apart from weight-loss medications, LillyDirect will also offer services for patients with diabetes and migraines.
The website’s pharmacy page will feature products like the migraine drug Emgality, insulin, and similar medications for home delivery.
Furthermore, the website will connect patients with independent telehealth providers who can either supplement their existing healthcare team or serve as an alternative to in-person care for specific conditions, according to the company’s statement.
Furthermore, the company will offer pharmacy services by partnering with third-party providers.
According to BMO Capital Markets analyst Evan Siegerman, Lilly’s decision is considered to be ahead of the curve. He believes that the direct-to-consumer (DTC) model is well-suited for obesity medications and will increase the adoption rate while reducing barriers for new patients starting Zepbound.
As a result, Lilly’s shares experienced a significant increase, reaching a record high of $631.18 during early trading, with a rise of up to 2.2%. The successful launch of Zepbound last month has generated optimism, leading to a 59% surge in the company’s shares throughout the previous year.
This remarkable performance has positioned Lilly as the largest healthcare firm based on market capitalization. Additionally, Lilly has made it clear that it opposes the use of its obesity and diabetes drugs, Mounjaro and Zepbound, for cosmetic weight loss purposes.